Grant Number:	5R01CA225647-04 Interpret this number
Primary Investigator:	Shih, Ya-Chen
Organization:	University Of Tx Md Anderson Can Ctr
Project Title:	Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors, and Economic Implications
Fiscal Year:	2022

PROJECT SUMMARY Targeted oral anticancer medications (TOAMs) have been the focus of oncology drug development in the past two decades. Although these novel agents contribute to survival improvement in several cancers and are convenient to administer, high drug prices have raised concerns on their affordability and possibly low treatment adherence driven by high out-of-pocket expenses. Current knowledge on the utilization and adherence of TOAMs is largely built upon studies of patients with chronic myelogenous leukemia. It remains unclear whether such knowledge is directly transferrable to other cancers, especially those with both oral and intravenous anticancer medications as viable treatment options. The specific aims of the study are: (1) to examine the utilization patterns of TOAMs as indicated vs. off-label use; (2) to estimate the impact of TOAM use on the overall costs of cancer care, costs of non-hormonal systemic therapies, as well as out-of-pocket payment; (3) to investigate the factors associated with the initiation of a TOAM and time to treatment initiation; and (4) to explore patterns of treatment switches and discontinuation and the associated factors among patients who started their systemic therapy with a TOAM. We will address our research questions using various cohorts of cancer patients extracted from three large claims databases: the SEER-Medicare, MarketScan, and Health Care Cost Institution data. We will conduct a series of studies to better understand the role of TOAMs in modern cancer care delivery by systematically studying the utilization pattern and economic impact of TOAMs as well as factors affecting the initiation and discontinuation of these novel therapies, paying special attention to financial factors for patients and providers. The findings from our study will inform patients, clinicians, and policy makers of the extent to which off-label prescription of TOAM is practiced in the real-world and the long-term economic impact of TOAM use, and provide critical information to guide reform or re-design of insurance policies to avoid creating financial disincentive to prescribe or use TOAM. Ultimately, the goal of our research is to improve the accessibility, affordability, effectiveness, and safety of TOAMs.




Cancer's Lasting Financial Burden: Evidence from a Longitudinal Assessment.
Authors: Shih Y.T. , Owsley K.M. , Nicholas L.H. , Yabroff K.R. , Bradley C. .
Source: Journal of the National Cancer Institute, 2022-03-24; , .
EPub date: 2022-03-24.
PMID: 35325197
Related Citations

Treating the Whole Patient With Cancer: The Critical Importance of Understanding and Addressing the Trajectory of Medical Financial Hardship.
Authors: Yabroff K.R. , Shih Y.T. , Bradley C.J. .
Source: Journal of the National Cancer Institute, 2022-03-08; 114(3), p. 335-337.
PMID: 34981116
Related Citations

A Coordinated Policy Approach to Address Medical Financial Toxicity.
Authors: Bradley C.J. , Yabroff K.R. , Shih Y.T. .
Source: JAMA oncology, 2021-12-01; 7(12), p. 1761-1762.
PMID: 34673882
Related Citations

Sensitivity of Psychosocial Distress Screening to Identify Cancer Patients at Risk for Financial Hardship During Care Delivery.
Authors: Maldonado J.A. , Fu S. , Chen Y.S. , Acquati C. , Yabroff K.R. , Banegas M.P. , Chang S. , Conti R.M. , Checka C.M. , Peterson S.K. , et al. .
Source: JCO oncology practice, 2021 12; 17(12), p. e1856-e1865.
EPub date: 2021-05-27.
PMID: 34043452
Related Citations

A look at the gynecologic oncologist workforce - Are we meeting patient demand?
Authors: Ackroyd S.A. , Shih Y.T. , Kim B. , Lee N.K. , Halpern M.T. .
Source: Gynecologic oncology, 2021 11; 163(2), p. 229-236.
EPub date: 2021-08-27.
PMID: 34456058
Related Citations

A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome.
Authors: Pan I.W. , Halperin D.M. , Kim B. , Yao J.C. , Shih Y.T. .
Source: PharmacoEconomics, 2021 11; 39(11), p. 1271-1297.
EPub date: 2021-08-11.
PMID: 34378163
Related Citations

Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market.
Authors: Shih Y.T. , Xu Y. , Zhao H. , Schrag D. , Yao J. .
Source: JNCI cancer spectrum, 2021 08; 5(4), .
EPub date: 2021-05-18.
PMID: 34350376
Related Citations

Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials.
Authors: Huey R.W. , George G.C. , Phillips P. , White R. , Fu S. , Janku F. , Karp D.D. , Naing A. , Piha-Paul S. , Subbiah V. , et al. .
Source: The oncologist, 2021 07; 26(7), p. 588-596.
EPub date: 2021-04-21.
PMID: 33783054
Related Citations

Time to add screening for financial hardship as a quality measure?
Authors: Bradley C.J. , Yabroff K.R. , Zafar S.Y. , Shih Y.T. .
Source: CA: a cancer journal for clinicians, 2021 03; 71(2), p. 100-106.
EPub date: 2020-11-23.
PMID: 33226648
Related Citations

State of Physician and Pharmacist Oncology Workforce in the United States in 2019.
Authors: Shih Y.T. , Kim B. , Halpern M.T. .
Source: JCO oncology practice, 2021 01; 17(1), p. e1-e10.
EPub date: 2020-12-03.
PMID: 33270520
Related Citations

Understanding Financial Hardship Among Cancer Survivors in the United States: Strategies for Prevention and Mitigation.
Authors: Yabroff K.R. , Bradley C. , Shih Y.T. .
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020-02-01; 38(4), p. 292-301.
EPub date: 2019-12-05.
PMID: 31804869
Related Citations

Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare Data.
Authors: Shih Y.T. , Xu Y. , Chien C.R. , Kim B. , Shen Y. , Li L. , Geynisman D.M. .
Source: PharmacoEconomics, 2019 12; 37(12), p. 1495-1507.
PMID: 31286464
Related Citations

Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
Authors: Shih Y.T. , Cortes J.E. , Kantarjian H.M. .
Source: The Lancet. Haematology, 2019 Aug; 6(8), p. e398-e408.
EPub date: 2019-06-14.
PMID: 31208943
Related Citations